Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These Tumors  by Koh, Youngil et al.
ORIGINAL ARTICLE
Clinicopathologic Characteristics and Outcomes of Patients
with Anaplastic Lymphoma Kinase-Positive Advanced
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Introduction: The purpose of this study was to analyze the clini-
copathologic characteristics and outcomes of patients with anaplas-
tic lymphoma kinase (ALK)-positive advanced pulmonary adenocar-
cinoma and to devise an effective screening strategy to identify such
patients.
Methods: We screened advanced pulmonary adenocarcinoma pa-
tients to identify ALK-positive cases. The presence of ALK rear-
rangements was confirmed by fluorescence in situ hybridization.
Results: Of the 221 screened patients, 45 demonstrated ALK rear-
rangements, and these individuals were younger than the ALK-
negative patients (p  0.001). The proportion of never smokers and
light smokers was found not to differ according to the ALK status
(p  0.537). Epidermal growth factor receptor (EGFR) mutations
and ALK rearrangements were found to be mutually exclusive.
Thyroid-transcription factor-1 (TTF-1) expression was observed in
all ALK-positive tumors for which immunohistochemistry data were
available. The objective response rate and progression-free survival
to first-line platinum-based chemotherapy showed no significant
differences between ALK-positive and ALK-negative patients. On
the other hand, no patient with ALK-positive tumors achieved
objective tumor responses to EGFR tyrosine kinase inhibitors
(TKIs). ALK rearrangements were not found among individuals who
had EGFR mutations, an objective response to a previous EGFR
TKI treatment or TTF-1-negative tumors.
Conclusion: The clinical outcomes of platinum-based chemother-
apy were found not to differ according to the ALK status. Both
smokers and never/light smokers should be candidates for ALK
screening. We suggest that the exclusion of patients with activating
EGFR mutations, an objective response to previous EGFR TKIs, or
TTF-1-negative tumors from ALK screening could be an effective
enrichment strategy for ALK-positive cases.
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Oncogenic addiction refers to the phenomenon of tumorcell dependence on an activated oncogene for their
survival and proliferation and provides an explanation for the
rapid regression of some tumors after targeted therapies.1 The
identification of an oncogenic addiction pathway is, therefore,
not only of great interest for cancer researchers but also of
great importance for improving treatment outcomes for pa-
tients with cancer. The translocation of the anaplastic lym-
phoma kinase (ALK) gene represents a recently discovered
oncogenic addiction pathway in lung cancer. The fusion of
ALK with echinoderm microtubule-associated protein-like-4
was first identified in 2007 in patients with non-small cell
lung cancer (NSCLC).2 This echinoderm microtubule-asso-
ciated protein-like-4-ALK gene fusion is created by an
inv(2)(p21p23) in lung cancer cells, and this fusion demon-
strates oncogenic potential in a mouse model.3 Fusion be-
tween kinesin family member 5B (KIF5B) and ALK has also
been identified in NSCLC, indicating that the ALK rearrange-
ments itself may represent a key pathogenic mechanism for
this cancer.4
Pharmacologic approaches to targeting ALK rearrange-
ments in patients with NSCLC have been successful thus far,
and encouraging results were observed recently in a phase I
trial of ALK inhibitor, crizotinib (PF-02341066; Pfizer, New
York, NY).5 This sponsor-initiated trial involved 82 patients
and reported an overall response rate (RR) of 57%. Based on
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these results, crizotinib should benefit a significant number of
patients with NSCLC with ALK rearrangements in the near
future.6 To effectively screen and identify patients with
NSCLC with ALK rearrangements, the specific characteristics
of ALK-positive tumors need to be adequately defined. Sev-
eral studies have reported that patients with ALK rearrange-
ments tend to be younger and to have never smoked.7,8
Pathologically, ALK-positive tumors are predominately ade-
nocarcinomas and contain signet ring cells.9 Furthermore,
ALK rearrangements and activating epidermal growth factor
receptor (EGFR) mutations are mutually exclusive.10,11 Al-
though these findings have yielded valuable preliminary data
on ALK-positive tumors, they did not provide precise infor-
mation on the clinicopathologic characteristics of ALK-posi-
tive advanced NSCLCs. Most previous reports have analyzed
surgical cases in the main. Moreover, there is little statistical
power associated with previous studies of ALK rearrange-
ments as the cohorts examined were small.
In this study, we screened patients with advanced
pulmonary adenocarcinoma for ALK rearrangements. Our
present report represents the largest series comparing ALK-
positive and ALK-negative advanced NSCLCs yet studied.
We analyzed the clinicopathologic characteristics and treat-
ment outcomes of our patient subjects, including their previ-
ous responses to platinum-based chemotherapy and EGFR
tyrosine kinase inhibitors (TKIs) treatment. In addition, we
suggested an effective future screening strategy to more
readily identify ALK-positive cases.
PATIENTS AND METHODS
Study Population
Patients with advanced pulmonary adenocarcinoma
whose tumor specimens underwent examination for ALK
status to find potential candidates of crizotinib treatment at
Seoul National University Hospital Oncology Clinic between
January 2008 and April 2010 were included in this study.
Each subject had a biopsy-proven pulmonary adenocarci-
noma, and these cancers were either metastatic or recurrent at
the time of ALK screening. Patient demographics and clini-
copathologic characteristics, including smoking history, his-
tologic subtype, EGFRmutations status, thyroid-transcription
factor-1 (TTF-1) protein expression status, RR, and progres-
sion-free survival (PFS) from previous chemotherapy, were
obtained from medical records. Patients who had smoked
more than 100 cigarettes in their lifetime were defined as
smokers. Among smokers, patients who had smoked 10
pack-years cigarettes were defined as light smokers. For
exsmokers (smoking cessation for at least 6 months), patients
who did not smoke for at least 10 years were defined as
remote smokers. The other exsmokers were defined as recent
exsmokers. Tumor histology and subtype were classified
according to the World Health Organization criteria.12 Acti-
vating EGFR mutations included the deletion of exon 19 and
a L858R point mutation in exon 21.13,14 Responses were
classified as complete response, partial response, stable dis-
ease, or progressive disease according to RECIST version
1.0.15 The PFS was calculated from the initiation of chemo-
therapy to the documentation of disease progression or death
from any cause. The study protocol was reviewed and ap-
proved by the institutional review board of Seoul National
University Hospital (H-1005-08-320) and adhered to the
recommendations of the Declaration of Helsinki for biomed-
ical research involving human subjects.
ALK Testing
Immunohistochemistry (IHC) or fluorescent in situ hy-
bridization (FISH) was used to screen tumor samples for ALK
status. ALK was classified as negative when either the IHC or
FISH result was negative. ALK FISH was performed in all the
cases that were IHC positive. ALK was defined as positive
only when the FISH result was positive.
ALK IHC was performed using a bond-max automated
immunostainer (Leica Microsystems, Milton Keynes, UK).
Paraffin sections (3 m) were evaluated by immunohisto-
chemical staining according to standard protocols. Each par-
affin section was dewaxed and subjected to antigen retrieval.
The use of antibodies was performed in accordance with the
manufacturer’s instructions. For antigen retrieval, the slides
were heated for 20 minutes at 100°C in Epitope Retrieval
Solution, pH 9.0 (Leica Microsystems). The slides were then
incubated with a mouse monoclonal antibody for ALK (No-
vocastra, Clone 5A4, Newcastle Upon Tyne, UK). Antibody
binding was detected using the Bond Polymer Refine Detec-
tion kit (Leica Microsystems). Mayer’s hematoxylin was
used as the counterstain. Various normal and cancer tissue
microarray blocks were included as positive and negative
controls. Tumor staining was assessed by two trained pathol-
ogists (D.H.C. and W.-H.K.) who were unaware of patient’s
clinical data. ALK IHC was considered positive if cytoplas-
mic staining was detected in 10% or more tumor cells.
For ALK FISH, 4-m-thick sections were deparaf-
finized, dehydrated, immersed in 0.2 N HCl, and incubated in
1 M NaSCN for 30 minutes at 80°C. Sections were then
immersed in pepsin solution. Dual-probe hybridization for
ALK was performed using the LSI ALK break-apart probe set
(Vysis, Downers Grove, IL). The probe mixture was applied
to the slides, which were then incubated in a humidified
atmosphere with HYBrite (Vysis) at 77°C for 5 minutes to
simultaneously denature the probe and target DNA. An ad-
ditional 16 hours at 37°C was required for hybridization.
Next, the slides were immersed in 0.3% NP-40/0.4 saline
sodium citrate for 5 minutes at room temperature, followed
by 0.3% NP-40/0.4 saline sodium citrate for 5 minutes at
72°C. The nuclei were counterstained with 4,6-diamidino-
2-phenylindole. ALK FISH was considered positive when
more than 15% of 50 or more analyzed cells showed splitting
apart of the fluorescent probes flanking the ALK locus.
Statistical Analysis
The variables included for analysis in this study were
age, gender, smoking history, histologic profile, EGFR mu-
tations status, TTF-1 protein expression status, ALK positiv-
ity, RR, and PFS after chemotherapy. Statistical analysis of
2  2 contingency tables of categorical variables was per-
formed using the Pearson’s 2 test or Fisher’s exact test, as
appropriate. The t test was performed to compare continuous
variables between two groups. The median durations of PFS
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were calculated using the Kaplan-Meier method, and com-
parisons between groups were made using log-rank tests. The
impact of continuous numeric variables on clinical outcome
was calculated using logistic regression and a Cox regression
model. All statistical tests were two sided, with significance
defined as p less than 0.05. All analyses were performed
using SPSS for Windows Version 12.0 (IBM, Chicago, IL).
RESULTS
Patient Characteristics
During the study period, a total of 221 patients with
advanced pulmonary adenocarcinoma were screened. Metastatic
disease was present at the time of diagnosis in 166 of these
cases. Fifty-five patients presented with operable or locally
advanced disease and progressed to advanced disease. Among
these 55 patients, 45 had received surgery and relapsed, eight
received concurrent chemoradiotherapy and then progressed,
and two did not receive any potentially curative treatment due to
a poor overall condition. At the time of screening for ALK
rearrangements, 192 of our patient subjects had undergone
palliative cytotoxic chemotherapy. Among this group, 170 pa-
tients received platinum-based (either cisplatin or carboplatin)
doublet chemotherapy as a first-line treatment. Three patients
received Avastin (bevacizumab; Roche, Basel, Switzerland)
with platinum-based doublet chemotherapy. The median PFS
for platinum-based doublet chemotherapy was 5.8 months.
EGFR TKI was administered to 113 of our patients, and the
resulting median PFS was 8.6 weeks. The signet ring cell
component was observed in five patients, and a bronchioloal-
veolar growth pattern was seen in 22 cases. EGFR mutations
analysis was performed in 135 patients and 46 cases showed
activating EGFR mutations. TTF-1 expression was evaluated in
82 patients and was positive in 62 of these cases (75.6%).
ALK Positivity
Of the 221 screened patients, 45 demonstrated ALK
rearrangements. Among 18 IHC-positive cases, 14 patients
were confirmed as ALK positive by ALK FISH. The other 31
patients were diagnosed as ALK positive by ALK FISH only.
Representative images of ALK IHC and ALK FISH are shown
in Figure 1.
Clinicopathologic Characteristics of
ALK-Positive Patients
No gender differences were observed (p 0.765) when
ALK-positive and -negative patients were compared. The
proportion of never smokers and light smokers was found not
to differ according to the ALK status (p  0.537). Among
smokers, the proportion of current smokers, recent exsmok-
ers, and remote smokers was not different according to the
ALK status (p  0.892). For exsmokers, no difference in the
proportion of remote smokers and recent exsmokers was
observed according to the ALK status (p  1.000), either. On
the other hand, ALK-positive patients were statistically
younger than ALK-negative patients (median age: 49 versus
61 years, p  0.001). Indeed, ALK positivity and age dem-
onstrated an inverse dose-response relationship (p  0.001).
When our patients were categorized into three groups accord-
ing to ALK status and EGFR mutations (ALK-positive cases,
EGFR mutant, or wild type), ALK-positive patients (median
age: 49 years) were found to be younger than both EGFR
mutant (median age: 63 years, p 0.001) cases and wild type
(median age: 61 years, p  0.001).
FIGURE 1. Representative examples
of anaplastic lymphoma kinase (ALK)
immunostaining (A and B) (400)
and ALK break-apart fluorescent in
situ hybridization (FISH) (C and D)
(1000). A, ALK-positive specimen
showing strong cytoplasmic staining.
B, ALK-negative case with negligible
ALK staining. C, Specimen with ALK
rearrangements. D, Specimen without
ALK rearrangements.
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Pathologically, signet ring cell components tended to
be frequently observed in ALK-positive tumors (p  0.056).
There was no correlation found between ALK positivity and
the bronchioloalveolar growth pattern (data not shown).
TTF-1 expression was observed in all ALK-positive tumors
for which IHC data were available. On the other hand, not a
single case without TTF-1 expression harbored ALK rear-
rangements. EGFR mutations and ALK rearrangements were
also found to be mutually exclusive. These results are sum-
marized in Tables 1 and 2.
Response to Platinum-Based Doublet
Chemotherapy and EGFR TKI
The response to platinum-based doublet chemotherapy
was found not to be influenced by the ALK status of the
patients with NSCLC. When evaluated in 154 patients with
measurable disease, the RR to first-line palliative platinum-
based doublet chemotherapy was 34.4% in the ALK-negative
group and 18.8% in the ALK-positive group (p  0.088). The
disease control rate associated with platinum-based doublet
chemotherapy was 82.8% in the ALK-negative group and
81.2% in the ALK-positive group (p  0.839). When patients
were categorized according to their EGFR mutations and
ALK status, the RR was 18.8%, 37.5%, and 40.4% in patients
with ALK rearrangements, EGFR mutants, and wild types,
respectively. The RR (p  0.091) and disease control rate
(p  0.979) were found not to differ among the three groups
(Table 3).
When the PFS of platinum-based doublet chemother-
apy was assessed, there were no significant differences found
between ALK-positive and ALK-negative patients (median
PFS: 6.2 versus 5.6 months, p  0.321, Figure 2A). Addi-
tionally, when patients are categorized according to their ALK
status and EGFR mutations, the PFS was similar among the
groups (median PFS: 6.2 months, 5.4 months, and 7.3 months
for ALK-positive patients, EGFR mutant, and wild types,
respectively; p  0.348; Figure 2B). When multivariate
analysis was performed considering age, gender, smoking
status, and ALK status to exclude possible impact of con-
founding factors, ALK status was not related to PFS (p 
0.296) (Table 4).
ALK positivity was determined to be a poor predictive
factor for the EGFR TKIs response in the 113 patients who
received this treatment. None of the ALK-positive patients
showed even a partial response to EGFR TKI, and a statisti-
cally significantly lower RR was observed compared with
ALK-negative patients (p 0.011). Three of 16 ALK-positive
patients showed stable disease to EGFR TKIs (disease control
rate 18.8%). Interestingly, ALK rearrangements were not
observed in any tumors which showed objective response to
EGFR TKI. When patients were categorized according to
their EGFR mutations and ALK status, RR of EGFR TKI was
0%, 50%, and 6.9% for patients with ALK rearrangements,
EGFR mutants, and wild types, respectively (Table 3). ALK-
positive patients also showed a shorter EGFR TKIs PFS
compared with ALK-negative patients (median PFS: 4.3 ver-
sus 13.6 weeks, p  0.001, Figure 2C). When patients were
categorized according to their ALK status and EGFR muta-
tions, the EGFR TKIs PFS was significantly longer in EGFR
mutants compared with the other two groups (median PFS:
4.3 weeks, 19.6 weeks, and 6.0 weeks for ALK-positive
patients, EGFR mutants, and wild types, respectively; p 
0.001; Figure 2D).
TABLE 1. Characteristics of 221 Patients According to the
ALK Rearrangements Status
Characteristics
ALK Positive
(N  45)
ALK Negative
(N  176)
pNo. Percentage No. Percentage
Age (median) 49 61 0.001
Age (stratified) 0.001
20–29 yr 4 8.9 0 0
30–39 yr 7 15.6 10 5.7
40–49 yr 12 26.7 28 15.9
50–59 yr 14 31.1 38 21.6
60–69 yr 5 11.1 62 35.2
70–79 yr 3 6.7 34 19.3
80–89 yr 0 0 4 2.3
Gender 0.765
Male 26 57.8 106 60.2
Female 19 42.2 70 39.8
Smoking amount 0.537
Never smoker 26 57.8 85 48.3
10 pack-years 5 11.1 11 6.2
10 pack-years 9 20.0 80 45.5
Unknown 5 11.1 0 0
Smoking cessation
status
0.892a
Never smoker 26 57.8 85 48.3
Remote
exsmokerb
4 8.9 22 12.5
Recent
exsmokerc
3 6.7 16 9.1
Current smoker 7 15.6 50 28.4
Unknownd 5 11.1 3 1.7
Signet ring cell
component
0.056
Present 3 6.7 2 1.1
Absent 41 91.1 173 98.3
Unknown 1 2.2 1 0.6
TTF-1 expression 0.033
Positive 12 26.7 50 27.4
Negative 0 0 20 11.4
Unknown 33 73.3 70 60.2
EGFR mutations 0.001
Positive 0 0 46 26.1
Negative 16 35.6 73 41.5
Unknown 29 64.4 57 32.4
a Comparison made among remote smoker, recent exsmoker and current smoker.
b Smoking cessation for 10 yr.
c Smoking cessation 10 yr.
d Either smoking status or smoking cessation status unknown.
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor;
TTF-1, thyroid-transcription factor-1.
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DISCUSSION
ALK rearrangements in lung cancer can potentially be
targeted using specific drugs.7 As is the case of EGFR,16,17
identification of the appropriate patient population for therapy
remains key to the overall success of such targeted therapies.
A recent phase I trial with the ALK inhibitor crizotinib seems
to have successfully identified the appropriate population
such as patients who are ALK positive by FISH. Nevertheless,
the development of this ALK inhibitor has just followed the
recent discovery of ALK rearrangements in lung cancer, and
therefore, not much is yet known about the clinicopathologic
characteristics of patients with ALK rearrangements. Because the
frequency of ALK rearrangements is just 1 to 4.9% in nonse-
lected patients with NSCLC,5,10,18–21 identification of the clini-
copathologic characteristics of ALK-rearranged tumors is be-
coming increasingly important to effectively screen for these
tumors. Previous studies in this regard have involved only small
numbers of ALK-positive patients or employed arbitrary patient
selections. Further studies are, therefore, clearly necessary to
provide additional information on ALK-positive tumors.
Our present study population comprised pulmonary
adenocarcinoma patients who had visited a single center. We
only included patients with metastatic disease, and surgical
cases were excluded. Furthermore, we screened these patients
for the possible use of crizotinib. Hence, the characteristics of
ALK-positive tumors determined by our current analyses
should be helpful for oncology clinics treating these cancers.
In our study, 45 of 221 patients (20.3%) demonstrated
ALK rearrangements. We postulate that at least two factors
should attribute to relatively high percentage of ALK-positive
patients in our study. First, 24 among 221 patients were
referred to our hospital for crizotinib clinical trials. These
referred patients were either screened for ALK rearrange-
ments or enriched by clinicopathologic characteristics at
other hospitals. Second, despite we did not intentionally
exclude any specific patient population from ALK screening,
TABLE 2. Comparison of Clinicopathologic Characteristics of Patients According to ALK
Rearrangements and EGFR Mutations Status
Characteristics
ALK Rearrangements
() (N  45)
EGFR Mutations ()
(N  46)
WT for EGFR/ALK
(N  73)
pNo. Percentage No. Percentage No. Percentage
Age (median) 49 63 61 0.001
Gender
Male 26 57.8 23 50.0 42 57.5
Female 19 42.2 23 50.0 31 42.5
Smoking amount 0.464
Never smoker 26 57.8 29 63.0 36 49.3
10 pack-years 5 11.1 2 4.3 4 5.5
10 pack-years 9 20.0 15 32.6 33 45.2
Unknown 5 11.1 0 0 0 0.0
Smoking cessation
status
0.270a
Never smoker 26 57.8 29 63.0 36 49.3
Remote exsmokerb 4 8.9 8 17.4 6 8.2
Recent exsmokerc 3 6.7 2 4.3 8 11.0
Current smoker 7 15.6 7 15.2 21 28.8
Unknownd 5 11.1 0 0 2 2.7
Signet ring cell
component
0.080
Present 3 6.7 1 2.2 1 1.4
Absent 41 91.1 45 97.8 72 98.6
Unknown 1 2.2 0 0 0 0
TTF-1 expression 0.042
Positive 12 26.7 12 26.1 24 32.9
Negative 0 0 3 6.5 9 12.3
Unknown 33 73.3 31 67.4 40 54.8
a Comparison made among remote smoker, recent exsmoker, and current smoker.
b Smoking cessation for 10 yr.
c Smoking cessation 10 yr.
d Either smoking status or smoking cessation status unknown.
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; WT, wild types; TTF-1, thyroid-transcription factor-1.
Journal of Thoracic Oncology • Volume 6, Number 5, May 2011 ALK-Positive Advanced Pulmonary Adenocarcinoma
Copyright © 2011 by the International Association for the Study of Lung Cancer 909
our patient cohort might include relatively higher proportion
of patients without EGFR mutations.
In this study, we observed that ALK-positive patients
have different demographics compared with ALK-negative
patients. ALK-positive patients were younger on average than
ALK-negative patients. No gender bias was evident for ALK
rearrangements in contrast to EGFR mutations, which are
more common in females. Interestingly, the proportion of
never smokers and light smokers was found not to differ
according to the ALK status. Although smoking histories can
vary over time and across cultures, and should, therefore, be
interpreted cautiously, we observed that 14 of 45 patients
(31.1%) with ALK rearrangements had a smoking history. To
investigate the possible impact of smoking on ALK rearrange-
ments, we further examined the amount of smoking and the
duration of smoking cessation according to the ALK status.
We subsequently found that smoking was not significantly
different according to the ALK status. In this regard, a
previous study by Shaw et al.8 should be interpreted carefully.
In this earlier study, patients were selected on the basis of two
FIGURE 2. Progression-free survival
(PFS) of platinum-based cytotoxic
chemotherapy (A and B) and epi-
dermal growth factor receptor
(EGFR) tyrosine kinase inhibitor
(TKI) treatments (C and D) adminis-
tered according to the anaplastic
lymphoma kinase (ALK) and EGFR
status. Although the ALK status does
not influence the PFS of cytotoxic
chemotherapy, ALK positivity is a
predictive factor for a short PFS af-
ter EGFR TKI treatment. *Wild type
for both ALK rearrangements and
EGFR mutation.
TABLE 3. Response to First-Line Platinum-Based Doublet Chemotherapy and EGFR TKIs
According to the ALK Rearrangements and EGFR Mutations Status
Characteristics
ALK
Rearrangements
()
EGFR
Mutations
()
WT for
EGFR/ALK
pNo. Percentage No. Percentage No. Percentage
Best response to platinum-based
chemotherapy
0.091a
No. of patients evaluated 32 24 57
CR 0 0 1 4.2 1 1.8
PR 6 17.6 8 33.3 22 38.6
SD 20 58.8 11 45.8 24 42.1
PD 6 17.6 4 16.7 10 17.5
Best response to EGFR TKIs 0.001a
No. of patients evaluated 16 18 29
CR 0 0 0 0 0 0
PR 0 0 9 50.0 2 6.9
SD 3 18.8 6 33.3 11 37.9
PD 13 81.2 3 16.7 16 55.2
a p value calculated by binary comparison (responder vs. nonresponder).
WT, wild type; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; TKIs, tyrosine kinase
inhibitors; ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor.
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or more of the following characteristics: Asian ethnicity,
never/light smoking history, and adenocarcinoma histology.
Moreover, the assumption for patient selection criteria was
that the demographics of patients with ALK rearrangements
and those with EGFR mutations would be similar. This
earlier study population is likely, therefore, not to be repre-
sentative of ALK-positive patients.
In addition, we confirmed from our data that ALK
rearrangements were not a predictive marker for conventional
platinum-based doublet chemotherapy. Shaw et al.8 showed
similar findings but did not achieve sufficient statistical
power due to the small number of patients in their ALK-
positive group. In this study cohort, 170 patients were eval-
uated for their chemotherapy response. Thirty-four patients
were ALK positive, and statistical power was achieved. Our
present data, thus, confirm that ALK rearrangements do not
predict the platinum-based chemotherapy response.
On the other hand, ALK rearrangements were identified
by our current analyses as a poor predictive marker for the
EGFR TKI response. This was an expected result and in
conjunction with previous findings for EGFR TKI treat-
ments22,23 validates the assertion that effective targeted ther-
apy requires the appropriate patient population to be selected.
This result also suggests that previous response to EGFR TKI
would be strongly helpful in ALK screening.
Pathologically, ALK rearrangements were found to be
mutually exclusive with EGFR mutations and to have strong
positive relationship with TTF-1 protein expression. The
association between TTF-1 expression and ALK positivity in
tumor samples have been assessed in parallel in previous
studies.9,10 In a previous study, not a single tumor without
TTF-1 expression harbored ALK rearrangement.9 Interest-
ingly, none of the tumors without TTF-1 expression harbored
ALK rearrangements in our study also (0/20). A high expres-
sion of TTF-1 in ALK-positive tumor is not explained by
linkage disequilibrium, however, and the genomic location of
TTF-1 (9q34.3) is unrelated to ALK. The pathways underly-
ing this phenomenon, thus, warrant further study.
Finally, we propose a future screening strategy for ALK
rearrangements based on our findings. From the above analyses,
we define three groups of tumors which do not harbor ALK
rearrangements at all and could be excluded from an ALK
screening. These are (1) tumors with activating EGFR muta-
tions, (2) tumors which show an objective response to previous
EGFR TKI treatments, and (3) tumors without TTF-1 expres-
sion. On the basis of our current findings, we propose an
algorithm for ALK screening (which is shown in Figure 3).
In conclusion, our present data indicate that advanced
pulmonary adenocarcinoma patients with ALK rearrange-
ments tend to be young with no gender predilection. More-
over, smoking history should not be used as a selection
criterion for ALK screening. In addition, the ALK status is not
a predictive marker for platinum-based chemotherapy and is
a significant negative predictive marker for the outcomes of
EGFR TKI treatments. We suggest that patients with activat-
ing EGFR mutations, objective responses to previous EGFR
TKIs, or harboring TTF-1-negative tumors could be excluded
from future ALK screening and that this will be an effective
enrichment strategy for ALK-positive cases.
TABLE 4. Hazard Ratio and p Value of Age, Gender,
Smoking Status, and ALK Rearrangements for the PFS of
First-Line Platinum-Based Doublet Chemotherapy in
Multivariate Analysis
Factors
Hazard
Ratio
95% Confidence Interval
Lower Upper p
Age 0.995 0.979 1.010 0.505
Gender 0.129
Male 1
Female 0.682 0.416 1.118
Smoking 0.281
No 1
Yes 0.766 0.472 1.244
ALK rearrangements 0.296
Absent 1
Present 0.761 0.456 1.270
ALK, anaplastic lymphoma kinase.
FIGURE 3. Suggested algorithm
for anaplastic lymphoma kinase
(ALK) screening in patients with ad-
vanced pulmonary adenocarcinoma
EGFR mutations status, TTF-1 ex-
pression, and previous response to
EGFR TKIs are helpful in decision
making for ALK screening. EGFR,
epidermal growth factor receptor;
TTF-1, thyroid-transcription factor 1;
TKI, tyrosine kinase inhibitor; CR,
complete response; PR, partial re-
sponse; SD, stable disease; PD, pro-
gressive disease.
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